WeVote
Log In

Bill

Bill

SB 3525

PRESCRIPTION HORMONE THERAPY

104th Regular Session Introduced by Lakesia Collins and 3 co-sponsors

Establishes standards for prescription hormone therapy, including prescriber qualifications, informed consent, monitoring, and reporting to improve safety and oversight.

0
WeVote Research Nonpartisan
Bill Summary · SB 3525

Overview

SB 3525 (104th Illinois General Assembly) concerns prescription hormone therapy. The bill is sponsored by a main sponsor with several co-sponsors. The summary below outlines the bill’s stated purpose, key provisions, who and what would be affected, and notable procedural or timeline details.

Purpose and intent

  • Establishes standards and regulatory framework related to prescription hormone therapy (PHT) within Illinois.
  • Aims to address patient safety, informed consent, prescriber qualifications, and monitoring requirements for individuals receiving prescription hormone therapies.
  • Seeks to ensure consistent clinical practices across providers and to enhance oversight of prescribing patterns and patient outcomes.

Key provisions

  • Prescriber qualifications and responsibilities: Sets criteria for who may prescribe prescription hormone therapy, including credentialing, continuing education, and adherence to evidence-based guidelines.
  • Informed consent and patient communication: Requires patients to receive comprehensive information about potential risks, benefits, alternatives, and monitoring plans before initiating therapy. May specify standardized consent forms or disclosures.
  • Treatment protocols and monitoring: Establishes minimum monitoring parameters (e.g., baseline testing, periodic follow-up, lab work, and risk assessment) to track efficacy and adverse effects.
  • Safety and risk management: Addresses contraindications, drug interactions, and alerts for adverse events. May include requirements for routine screening (e.g., cardiovascular, metabolic, thromboembolic risk) depending on therapy type.
  • Documentation and recordkeeping: Mandates specific recordkeeping practices to document indications, dosage, duration, patient consent, laboratory results, and clinician notes.
  • Reporting and data collection: Sets up mechanisms for reporting adverse events and may authorize collection of aggregate data to assess safety and efficacy across populations.
  • Access and equity considerations: May include provisions intended to ensure equitable access to PHT and prevent discriminatory practices in prescribing or insurance coverage.
  • Enforcement and penalties: Outlines regulatory enforcement options for noncompliance, potential penalties, and remedies for patients or third parties.

Who and what would be affected

  • Healthcare providers who prescribe or participate in prescription hormone therapies (e.g., physicians, nurse practitioners, physician assistants).
  • Patients receiving or seeking prescription hormone therapy.
  • Healthcare facilities and clinics offering hormone therapy services.
  • Insurers and payer systems subject to requirements around coverage or documentation related to PHT.
  • State regulatory agencies responsible for professional licensure, prescribing oversight, and public health monitoring.

Procedural and timeline aspects

  • The bill would become law upon passage and signing (or as otherwise specified within the bill’s effective date provisions, such as phased implementation or delayed effective dates).
  • Implementation could involve rulemaking by relevant state agencies to specify technical standards, forms, reporting systems, and compliance timelines.
  • Potential phased rollout if the bill includes multiple effective dates for different provisions or for certain provider groups.

Potential impact and considerations

  • Patient safety: Enhanced monitoring and standardized practices aim to reduce risks associated with PHT.
  • Provider practice: May require additional training, documentation, and adherence to protocols, influencing workflow.
  • Access and equity: Provisions could affect access to PHT through coverage guidelines or streamlined processes, as well as protections against disparities.
  • Data and oversight: Increased data collection could improve public health understanding of PHT outcomes but may raise privacy considerations.

Note: This summary is based on the bill’s general description and common elements of prescription hormone therapy regulatory proposals. For precise language, definitions, scope, effective dates, exemptions, and penalties, please refer to the official bill text and fiscal notes.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.